Peroxisome Proliferator-Activated Receptors
"Peroxisome Proliferator-Activated Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.
| Descriptor ID |
D047492
|
| MeSH Number(s) |
D12.776.826.239 D12.776.930.705
|
| Concept/Terms |
Peroxisome Proliferator-Activated Receptors- Peroxisome Proliferator-Activated Receptors
- Peroxisome Proliferator Activated Receptors
- Proliferator-Activated Receptors, Peroxisome
- Receptors, Peroxisome Proliferator-Activated
- PPAR
|
Below are MeSH descriptors whose meaning is more general than "Peroxisome Proliferator-Activated Receptors".
Below are MeSH descriptors whose meaning is more specific than "Peroxisome Proliferator-Activated Receptors".
This graph shows the total number of publications written about "Peroxisome Proliferator-Activated Receptors" by people in this website by year, and whether "Peroxisome Proliferator-Activated Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peroxisome Proliferator-Activated Receptors" by people in Profiles.
-
Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development. Eur J Pharmacol. 2024 Feb 05; 964:176304.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov. 2023 05 04; 13(5):1230-1249.
-
PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. Cancer Lett. 2022 10 01; 545:215832.
-
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife. 2017 11 16; 6.
-
Novel mechanisms of endothelial mechanotransduction. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2378-86.
-
microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. PLoS One. 2013; 8(9):e75882.
-
The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar; 106(3):319-28.
-
Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring). 2008 Dec; 16(12):2593-600.
-
Smoking, inflammatory patterns and postprandial hypertriglyceridemia. Atherosclerosis. 2009 Apr; 203(2):633-9.